We use cookies and similar technologies for analytics, to understand how the site is used. You can accept or decline non-essential cookies. See our Privacy Policy.
Daily historical data with per-account defaults
Filings, earnings, research, and institutional changes — newest first
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
Consensus vs. actual, and revenue trend
| 분기 | 발표일 | 시각 | EPS 예상 | EPS 실제 | 서프라이즈 | 매출 예상 | 매출 실제 | 상태 |
|---|---|---|---|---|---|---|---|---|
| — | 2026. 08. 04. | 장 마감 후 (AMC) | $-0.98 | — | — | — | — | 예정 |
Consensus PT $27.62 · 13 analysts
| 날짜 | 리서치펌 | 애널리스트 | 액션 | 의견 변화 | 목표가 | 리포트 |
|---|---|---|---|---|---|---|
| 2026. 05. 12. | Needham | — | 의견 유지 | Buy → Buy | — | Needham: Buy |
| 2026. 05. 11. | HC Wainwright & Co. | — | 의견 유지 | Buy → Buy | — | HC Wainwright & Co.: Buy |
동일 리서치펌의 과거 의견 변화, 동일 섹터 내 다른 종목 액션과 비교 가능
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
Automated summary from public sources · not investment advice
공시·실적·기관 변화를 한국어 한 단락으로 요약. 원문 출처와 함께 제공됩니다.
Ranked by position value
| # | 기관 | 운용 형태 | 보유 주식 | 평가액 | 비중 | 변화율 | 포지션 |
|---|---|---|---|---|---|---|---|
| 1 | Point72 Asset Management, L.P. | Point72 Asset Management, L.P. | 1,368,518 | $25.51B | 0.05% | — | 신규 편입 |
| 2 | TWO SIGMA INVESTMENTS, LP | TWO SIGMA INVESTMENTS, LP | 1,122,312 | $20.92B | 0.02% | — | 신규 편입 |
신규 편입·전량 매도·비중 변화까지 모두 확인할 수 있습니다.
MoonLake Immunotherapeutics, a clinical-stage biotechnology company, focuses on developing therapies for inflammatory skin and joint diseases. It develops Sonelokimab, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody for the treatment of inflammatory diseases in dermatology and rheumatology, as well as for hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, palmoplantar pustulosis, and psoriasis. The company was founded in 2021 and is headquartered in Zug, Switzerland.
Stored first · Google News · Yahoo Finance (English)
MoonLake Immunotherapeutics Signs Manufacturing Agreement with Vetter Pharma – SEC 8-K Filing Details 8 - Minichart
MoonLake Immunotherapeutics Signs Manufacturing Agreement with Vetter Pharma – SEC 8-K Filing Details 8 Minichart
MoonLake Immunotherapeutics enters supply and capacity agreements with Vetter - Investing.com
MoonLake Immunotherapeutics enters supply and capacity agreements with Vetter Investing.com
MoonLake (NASDAQ: MLTX) secures Vetter supply and capacity agreements - Stock Titan
MoonLake (NASDAQ: MLTX) secures Vetter supply and capacity agreements Stock Titan
HC Wainwright & Co. Maintains MoonLake Immunotherapeutics (MLTX) Buy Recommendation - MSN
HC Wainwright & Co. Maintains MoonLake Immunotherapeutics (MLTX) Buy Recommendation MSN
How Moonlake Immunotherapeutics (MLTX) Affects Rotational Strategy Timing - Stock Traders Daily
How Moonlake Immunotherapeutics (MLTX) Affects Rotational Strategy Timing Stock Traders Daily
Should FDA Alignment on Sonelokimab’s HS Label Strategy Require Action From MoonLake Immunotherapeutics (MLTX) Investors? - simplywall.st
Should FDA Alignment on Sonelokimab’s HS Label Strategy Require Action From MoonLake Immunotherapeutics (MLTX) Investors? simplywall.st